Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Rev. bras. reumatol ; 55(2): 185-188, Mar-Apr/2015. tab, graf
Article in Portuguese | LILACS | ID: lil-746151

ABSTRACT

A infecção pelo Parvovírus B19 costuma ser assintomática, mas as expressões clínicas podem incluir crise aplástica transitória, eritema infeccioso, hidropisia fetal não imune e aplasia crônica da série vermelha. Esse vírus também se associa à artrite reumatoide e a outras doenças autoimunes do tecido conjuntivo; entretanto, não conseguimos identificar na literatura nenhum caso de miosite aguda em adulto desenvolvida depois de infecção pelo Parvovírus B19. Por essa razão, gostaríamos de apresentar um caso raro de miosite aguda desenvolvida depois de infecção pelo Parvovírus B19. Nos pacientes que apresentam sintomas de febre, rash nas pernas e miosite, devem ser consideradas as infecções virais, como a causada pelo Parvovírus B19.


Parvovirus B19 infection is often asymptomatic, but clinical expressions may include transient aplastic crisis, erythema infectiosum, non-immune hydrops fetalis, and chronic red cell aplasia. This virus has also been associated with rheumatoid arthritis and other autoimmune connective tissue diseases; however, we could not identify any acute adult myositis case developed after a Parvovirus B19 infection in the literature. For this reason, we would like to present a rare case of acute myositis developed after Parvovirus B19 infection. In patients presenting with symptoms of fever, rash on the legs and myositis, viral infections such as Parvovirus B19 should be kept in mind.


Subject(s)
Humans , Male , Adult , Erythema Infectiosum , Myositis/virology , Acute Disease
2.
Clinics ; 65(6): 593-597, 2010. tab, ilus
Article in English | LILACS | ID: lil-553965

ABSTRACT

BACKGROUND: Plasma D-dimer levels are directly related to the intra- and extra-vascular coagulation that occurs in acute and chronic lung damage in patients with community-acquired pneumonia (CAP). OBJECTIVES: This study examines the relationship between the severity of community-acquired pneumonia and D-dimer levels. In addition, the study examines the correlations among community-acquired pneumonia, the radiological extent of the disease and mortality. METHODS: The Pneumonia Severity Index was used to classify patients into five groups. Patients were treated at home or in the hospital according to the guidelines for community-acquired pneumonia. Blood samples were taken from the antecubital vein with an injector and placed into citrated tubes. After they were centrifuged, the samples were evaluated with the quantitative latex method. RESULTS: The study included 60 patients who had been diagnosed with community-acquired pneumonia (mean age 62.5 ± 11.7) and 24 healthy controls (mean age 59.63 ± 6.63). The average plasma D-dimer levels were 337.3 ± 195.1ng/mL in the outpatient treatment group, 691.0 ± 180.5 in the inpatient treatment group, 1363.2 ± 331.5 ng/mLin the intensive care treatment group and 161.3 ± 38.1ng/mL in the control group (p<0.001). The mean D-dimer plasma level was 776.1 ± 473.5ng/mL in patients with an accompanying disease and 494.2 ± 280.1 ng/mL in patients without an accompanying disease (p<0.05). CONCLUSIONS: Plasma D-dimer levels were increased even in community-acquired pneumonia patients who did not have an accompanying disease that would normally cause such an increase.


Subject(s)
Female , Humans , Male , Middle Aged , Fibrin Fibrinogen Degradation Products/analysis , Pneumonia/blood , Pneumonia/mortality , Biomarkers/blood , Brazil/epidemiology , Case-Control Studies , Community-Acquired Infections/blood , Community-Acquired Infections/mortality , Community-Acquired Infections/therapy , Fibrin Fibrinogen Degradation Products/metabolism , Hospital Mortality , Pneumonia/therapy , Severity of Illness Index , Survival Rate
3.
Clinics ; 65(5): 491-496, 2010. tab
Article in English | LILACS | ID: lil-548629

ABSTRACT

OBJECTIVE: The objective of this study was to present special clinical and laboratory features of 294 cases of mushroom poisoning. MATERIALS AND METHODS: In this retrospective study, 294 patients admitted to the Pediatric and Adult Emergency, Internal Medicine and ICU Departments of Cumhuriyet University Hospital were investigated. RESULTS: Of 294 patients between the ages of 3 and 72 (28.97 ± 19.32), 173 were female, 121 were male and 90 were under the age of 16 years. One hundred seventy-three patients (58.8 percent) had consumed the mushrooms in the early summer. The onset of mushroom toxicity symptoms was divided into early (within 6 h after ingestion) and delayed (6 h to 20 d). Two hundred eighty-eight patients (97.9 percent) and six (2.1 percent) patients had early and delayed toxicity symptoms, respectively. The onset of symptoms was within two hours for 101 patients (34.3 percent). The most common first-noticed symptoms were in the gastrointestinal system. The patients were discharged within one to ten days. Three patients suffering from poisoning caused by wild mushrooms died from fulminant hepatic failure. CONCLUSION: Education of the public about the consumption of mushrooms and education of health personnel working in health centers regarding early treatment and transfer to hospitals with appropriate facilities are important for decreasing the mortality.


Subject(s)
Adult , Aged , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Young Adult , Mushroom Poisoning/epidemiology , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Blood Urea Nitrogen , Biomarkers/blood , Emergency Medical Services , Mushroom Poisoning/therapy , Retrospective Studies , Turkey/epidemiology
4.
Clinics ; 65(1): 9-13, 2010. graf, tab
Article in English | LILACS | ID: lil-538601

ABSTRACT

Objectives: The aim of this study was to examine the frequency of Cushing's syndrome (CS) in obese patients devoid of specific clinical symptoms of Cushing's syndrome. Methods: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were included in the study. As a first screening step, we measured 24-h urinary free cortisol (UFC). An overnight 1-mg dexamethasone suppression test was also performed on all patients. Urinary free cortisol levels above 100 ìg/24 h were considered to be abnormal. Suppression of serum cortisol <1.8 ìg/dL after administration of 1 mg dexamethasone was the cut-off point for normal suppression. The suppression of the serum cortisol levels failed in all of the patients. Results: Measured laboratory values were as follows: ACTH, median level 28 pg/ml, interquartile range (IQR) 14-59 pg/ml; fasting glucose, 100 (91-113) mg/dL; insulin, 15.7 (7.57-24.45) mU/ml; fT4, 1.17 (1.05-1.4) ng/dL; TSH, 1.70 (0.91-2.90) mIU/L; total cholesterol, 209 (170.5-250) mg/dL; LDL-c, 136 (97.7-163) mg/dL; HDL-c, 44 (37.25-50.75) mg/dL; VLDL-c, 24 (17-36) mg/dL; triglycerides, 120.5 (86-165) mg/dL. The median UFC level of the patients was 30 ìg/24 h (IQR 16-103). High levels of UFC (>100 ìg/24 h) were recorded in 37 patients (24 percent). Cushing's syndrome was diagnosed in 14 of the 150 patients (9.33 percent). Etiologic reasons for Cushing's syndrome were pituitary microadenoma (9 patients), adrenocortical adenoma (3 patients), and adrenocortical carcinoma (1 patient). Conclusion: A significant proportion (9.33 percent) of patients with simple obesity were found to have Cushing's syndrome. These findings argue that obese patients should be routinely screened for Cushing's syndrome.


Subject(s)
Adult , Female , Humans , Male , Cushing Syndrome/diagnosis , Obesity/complications , Biomarkers/urine , Brazil/epidemiology , Cushing Syndrome/epidemiology , Cushing Syndrome/etiology , Dexamethasone/administration & dosage , Dexamethasone , Glucocorticoids/administration & dosage , Glucocorticoids , Hydrocortisone/urine , Obesity/urine , Reference Values
5.
Clinics ; 64(12): 1195-1200, 2009. tab
Article in English | LILACS | ID: lil-536222

ABSTRACT

AIM: In our study, we investigated the levels of glutamic acid decarboxylase antibody (anti-GAD), islet cell antibody (ICA), thyroperoxidase antibody (anti-TPO), thyroglobulin antibody (anti-TG), antinuclear antibodies (FANA), antibodies to double-stranded DNA (anti-ds DNA), antibody to Sjõgren syndrome A antigen (anti-SSA), antibody to Sjõgren syndrome B antigen (anti-SSB), Smith antibody (anti-Sm), smooth muscle antibodies (ASMA), and antimitochondrial antibody liver-kidney microsome (AMA-LKM) in patients with celiac disease as compared to healthy controls and autoimmune hypothyroid patients. MATERIALS AND METHODS: A total of 31 patients with celiac disease, 34 patients with autoimmune hypothyroidism and 29 healthy subjects were included in this study. Anti-SSA, anti-SSB, anti-Sm, anti-ds DNA, anti-GAD, anti-TPO and anti-TG were studied by Enzyme-Linked Immunosorbent Assay (ELISA), and AMA-LKM, ASMA, ANA and ICA were studied by immunofluorescence. Clinical data and the results of free thyroxine-thyroid stimulating hormone (FT4-TSH) were collected from the patients' files by retrospective analysis. SPSS ver 13.0 was used for data analysis, and the χ2 method was used for comparisons within groups. RESULTS: The frequency of anti-SSA, anti-SSB, anti-GAD, anti-Sm, anti-ds DNA, AMA-LKM, ASMA, ANA and ICA were not significantly different between the groups. Levels of anti-TPO and anti-TG antibodies were found to be significantly higher (<0.001) in autoimmune hypothyroid patients when compared with other groups. CONCLUSION: In previous studies, an increased frequency of autoimmune diseases of other systems has been reported in patients with celiac disease. We found that the frequency of autoimmune antibodies specific for other autoimmune diseases was not higher in celiac disease.


Subject(s)
Adult , Female , Humans , Male , Autoantibodies/blood , Celiac Disease/immunology , Autoantibodies/classification , Autoimmune Diseases/immunology , Case-Control Studies , Hypothyroidism/immunology , Retrospective Studies
6.
Clinics ; 63(5): 651-660, 2008. tab
Article in English | LILACS | ID: lil-495041

ABSTRACT

OBJECTIVES: The aim of this study was to investigate serum leptin, adiponectin and paraoxonase1 levels in adult females receiving pharmacotherapy for various psychiatric disorders. METHODS: The study group consisted of 32 obese females (mean age 40.53 ± 11.00 years, mean body mass index 35.44 ± 5.33 kg/m2) who were receiving treatment for psychiatric disorders, and the control group included 22 obese females (mean age 35.95 ± 9.16 years, mean body mass index 30.78 ± 3.33 kg/m2) who were free of psychiatric disorders. Analyses were performed using a bioelectrical impedance device. Fasting blood samples were obtained for complete blood count and various biochemical tests, including determination of leptin, adiponectin and paraoxonase1 activity. RESULTS: Body mass index, waist and hip circumference, body fat percentage, fasting blood glucose, insulin, glycosylated hemoglobin, homeostasis model assesment of insulin resistance, alanine transaminase, aspartate tarnsaminase, and leptin levels were significantly higher in the study group than in controls. Although body weight was positively correlated with leptin levels in both groups, body weight was negatively correlated with adiponectin levels in the control group and positively correlated with adiponectin levels in the study group. In the study group, body mass index and hip circumference correlated positively with leptin levels, hip circumference correlated positively with adiponectin levels, and waist to hip ratio correlated positively with paraoxonase levels. In the control group, body mass index as well as waist and hip circumferences were positively correlated with leptin levels. Weight, body mass index, and hip circumference were also negatively correlated with the adiponectin/leptin ratio in the control group. CONCLUSION: This study indicates a higher risk for obesity-related disorders, particularly metabolic syndrome, diabetes and cardiovascular disease, in patients treated with psychiatric drugs.


Subject(s)
Adult , Female , Humans , Aryldialkylphosphatase/blood , Cardiovascular Diseases/blood , /blood , Leptin/blood , Metabolic Syndrome/blood , Adiponectin/blood , Antidepressive Agents/adverse effects , Antidepressive Agents/therapeutic use , Body Mass Index , Biomarkers/blood , Case-Control Studies , Cardiovascular Diseases/etiology , /etiology , Mental Disorders/drug therapy , Metabolic Syndrome/etiology , Obesity/blood , Obesity/chemically induced , Waist-Hip Ratio
SELECTION OF CITATIONS
SEARCH DETAIL